ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,127 GBX | -0.32% |
|
-1.96% | +14.42% |
| May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
| May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |  |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 1,166 M€ | +0.26% | - | |
| 0.38% | 607 M€ | +0.05% | - | |
| 0.37% | 25 M€ | +3.42% | - | |
| 0.28% | 391 M€ | +9.31% | - | |
| 0.27% | 0 M€ | 0.00% | - | |
| 0.25% | 36 M€ | +3.15% | - | |
| 0.25% | 34 M€ | +9.38% | - | |
| 0.24% | 45 M€ | 0.00% | - | |
| 0.21% | 242 M€ | +9.62% | ||
| 0.18% | 306 M€ | +6.57% | - | |
| 0.18% | 39 M€ | +6.61% | - | |
| 0.17% | 20 M€ | +1.28% | - | |
| 0.17% | 7 M€ | +0.11% | - | |
| 0.14% | 17 M€ | +3.53% | - | |
| 0.14% | 105 M€ | +4.05% | - | |
| 0.13% | 253 M€ | +7.93% | ||
| 0.09% | 34 M€ | +4.26% | - | |
| 0.08% | 234 M€ | +6.34% | - | |
| 0.07% | 8 M€ | +1.24% | - | |
| 0.07% | 54 M€ | +0.94% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | -1.43% | - | |
| 0.01% | 146 M€ | -1.86% | - | |
| 0.01% | 25 M€ | -2.62% | - |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.6
USD
Spread / Average Target
+8.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.42% | 239B | |
| +32.36% | 694B | |
| +29.61% | 593B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| -3.39% | 209B | |
| +10.19% | 209B | |
| +9.27% | 169B | |
| +0.45% | 164B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC
